CytomX Therapeutics (CTMX) Non-Current Deffered Revenue (2016 - 2025)
Historic Non-Current Deffered Revenue for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $5.5 million.
- CytomX Therapeutics' Non-Current Deffered Revenue fell 8349.92% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 8349.92%. This contributed to the annual value of $26.9 million for FY2024, which is 6644.26% down from last year.
- CytomX Therapeutics' Non-Current Deffered Revenue amounted to $5.5 million in Q3 2025, which was down 8349.92% from $10.2 million recorded in Q2 2025.
- In the past 5 years, CytomX Therapeutics' Non-Current Deffered Revenue registered a high of $267.8 million during Q1 2021, and its lowest value of $5.5 million during Q3 2025.
- In the last 5 years, CytomX Therapeutics' Non-Current Deffered Revenue had a median value of $140.9 million in 2023 and averaged $130.7 million.
- Per our database at Business Quant, CytomX Therapeutics' Non-Current Deffered Revenue skyrocketed by 2552.18% in 2021 and then tumbled by 8349.92% in 2025.
- Quarter analysis of 5 years shows CytomX Therapeutics' Non-Current Deffered Revenue stood at $243.9 million in 2021, then dropped by 26.19% to $180.1 million in 2022, then plummeted by 55.54% to $80.0 million in 2023, then tumbled by 66.44% to $26.9 million in 2024, then tumbled by 79.39% to $5.5 million in 2025.
- Its Non-Current Deffered Revenue was $5.5 million in Q3 2025, compared to $10.2 million in Q2 2025 and $16.2 million in Q1 2025.